Interventional Pulmonology Market
Interventional pulmonology market generated $3.7 billion in 2021, & is anticipated to generate $6.9 billion by 2031, witnessing CAGR of 6.7% from 2022 to 2031.
PORTLAND, OR, UNITED STATES, August 7, 2023/EINPresswire.com/ — Interventional pulmonology refers to the use of minimally invasive techniques to diagnose and treat lung diseases. The interventional pulmonology market includes devices, procedures, and services related to this field.
The global interventional pulmonology market generated $3.7 billion in 2021, and is anticipated to generate $6.9 billion by 2031, witnessing a CAGR of 6.7% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/request-sample/32346
๐๐ซ๐ข๐ฏ๐๐ซ๐ฌ, ๐๐๐ฌ๐ญ๐ซ๐๐ข๐ง๐ญ๐ฌ, ๐๐ง๐ ๐๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ-
An increase in the prevalence of lung disease has led to a growing demand for pulmonology treatments, which is driving the growth of the global interventional pulmonology market. On the other hand, insurance companies and governments around the world are increasingly putting in place regulations that encourage the use of generic medications, further boosting the market competition. This is due to the fact that generic medications are regarded as cost-effective alternatives that can significantly lower healthcare expenses for governments and insurance providers. Generic medications are widely available at much lower prices as a result, creating a highly competitive market where it is challenging for brand-name medications to maintain their market share. These factors hindered the growth of the interventional pulmonology market growth.
Furthermore, spirometers, peak flow meters, and pulse oximeters are examples of advanced pulmonology devices which have made it convenient to diagnose and monitor respiratory diseases, which is estimated to generate new opportunities for the growth of the global interventional pulmonology industry in the future.
๐๐ก๐๐ญ ๐ข๐ฌ ๐ญ๐ก๐ ๐๐ฆ๐ฉ๐๐๐ญ ๐จ๐ ๐๐จ๐ฏ๐ข๐-๐๐ ๐๐๐ง๐๐๐ฆ๐ข๐ ๐จ๐ง ๐๐ง๐ญ๐๐ซ๐ฏ๐๐ง๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ฎ๐ฅ๐ฆ๐จ๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐ฅ๐จ๐๐๐ฅ๐ฅ๐ฒ?
The market for interventional pulmonology had experienced both opportunities and challenges as a result of COVID-19. The pandemic had made respiratory care more important than ever, which had increased demand for related goods and services. Also, the pandemic disrupted the global supply chains and reduced market investments.
Almost all industries were affected by the outbreak of COVID-19, and companies that produced interventional pulmonology had to stop operating because of import-export restrictions, lockdowns implemented in various countries, and a significant labor shortage.
However, the global market for interventional pulmonology has recovered slowly and steadily in the post-pandemic.
๐๐ก๐ ๐ก๐จ๐ฌ๐ฉ๐ข๐ญ๐๐ฅ๐ฌ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ ๐ญ๐จ ๐ฆ๐๐ข๐ง๐ญ๐๐ข๐ง ๐ข๐ญ๐ฌ ๐ฅ๐๐๐๐๐ซ๐ฌ๐ก๐ข๐ฉ ๐ฌ๐ญ๐๐ญ๐ฎ๐ฌ ๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก๐จ๐ฎ๐ญ ๐ญ๐ก๐ ๐๐จ๐ซ๐๐๐๐ฌ๐ญ ๐ฉ๐๐ซ๐ข๐จ๐-
The hospitals segment held the highest market share in 2021, accounting for nearly half of the global interventional pulmonology market, and is estimated to maintain its leadership status throughout the forecast period. The same segment would also cite the fastest CAGR of 7.4% from 2022 to 2031. The growth is attributed to numerous factors, such as the growth of the healthcare infrastructure, the expansion of hospitals, the aging of the population, and the presence of a large amount of patient population. The market for interventional pulmonology is expanding rapidly because of technological advances and a rise in the availability of specialized services in hospitals. As respiratory disorders have become more prevalent worldwide, there is a greater need for interventional pulmonary services.
๐๐ซ๐จ๐๐ฎ๐ซ๐ ๐๐จ๐ฆ๐ฉ๐ฅ๐๐ญ๐ ๐๐๐ฉ๐จ๐ซ๐ญ (๐๐๐ ๐๐๐ ๐๐ฌ ๐๐๐ ๐ฐ๐ข๐ญ๐ก ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ, ๐๐ก๐๐ซ๐ญ๐ฌ, ๐๐๐๐ฅ๐๐ฌ, ๐๐ง๐ ๐ ๐ข๐ ๐ฎ๐ซ๐๐ฌ) @ https://www.alliedmarketresearch.com/checkout-final/interventional-pulmonology-market
๐๐ก๐ ๐๐ซ๐จ๐ง๐๐ก๐จ๐ฌ๐๐จ๐ฉ๐๐ฌ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ ๐ญ๐จ ๐ซ๐ฎ๐ฅ๐ ๐ญ๐ก๐ ๐ซ๐จ๐จ๐ฌ๐ญ-
The bronchoscopes segment held the largest share in 2021, garnering nearly one-fourth of the global interventional pulmonology market revenue, and is projected to rule the roost by 2031. The same segment would also display the fastest CAGR of 8.3% from 2022 to 2031. Bronchoscope advancement and development, including white-light, autofluorescence (blue-light), navigational, and other varieties are one of the primary drivers in bronchoscope dominance as a product segment. Thus, the bronchoscope has recently been developed as a result of technological advancements, and its potential uses have expanded the market growth.
๐๐จ๐ซ๐ญ๐ก ๐๐ฆ๐๐ซ๐ข๐๐ ๐ ๐๐ซ๐ง๐๐ซ๐๐ ๐ญ๐ก๐ ๐ฆ๐๐ฃ๐จ๐ซ ๐ฌ๐ก๐๐ซ๐ ๐ข๐ง ๐๐๐๐-
North America contributed to the highest market share in terms of revenue in 2021, holding around two-fifths of the global interventional pulmonology market, and is likely to dominate the market throughout the forecast period. Increased healthcare spending, scientific advances in the detection and treatment of pulmonary disorders, and a move toward minimally invasive surgery in developed nations like the United States are contributing to the market’s growth. Moreover, frequent lung disorders brought on by smoking and an increase in air pollution are significant market growth drivers. However, the Asia-Pacific region is expected to showcase the fastest CAGR of 7.6% from 2022 to 2031. India and China are likely to be lucrative market for interventional pulmonology during the forecast period.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ- https://www.alliedmarketresearch.com/purchase-enquiry/32346
๐๐ง๐ญ๐๐ซ๐ฏ๐๐ง๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ฎ๐ฅ๐ฆ๐จ๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐๐๐๐ข๐ง๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ-
Olympus Corporation
clarus medical llc
Becton
Vygon
cook medical
Fujifilm corporation
Medtronic Plc
Huger Medical Instrument Co. Ltd
Smith’s Group Plc
Boston Scientific Corporation
๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ:
Gene Synthesis Market: https://www.alliedmarketresearch.com/gene-synthesis-market-A39015
Influenza Vaccine Market: https://www.alliedmarketresearch.com/influenza-vaccines-market
๐๐จ๐ง๐ญ๐๐๐ญ:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
David Correa
Allied Analytics LLP
1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
